October 2025 - Page 3 of 3 - BioMedWire (BMW)

WednesdayOct 08, 2025 10:30 am

Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability

Oncotelic Therapeutics developed the Deciparticles(TM) technology to improve the bioavailability of drugs, largely thanks to the creation of sub-20nm size of the nanoparticles Sapu Nano, part of Oncotelic’s GMP Bio joint venture, receives clearance to begin Phase 1 trial of Sapu003, an injectable form of Everolimus (Afinitor(R)) for breast cancer In preclinical studies, Sapu003 could raise the bioavailability of Everolimus (Afinitor(R)) from around 10%, as oral pill, up to anywhere from 80 to 100%, as injectable Result hopes for higher bioavailability in that drugs may have dramatically better, faster, and more consistent efficacy for patients Oncotelic Therapeutics (OTCQB: OTLC) is a…

TuesdayOct 07, 2025 10:30 am

HeartBeam Inc. (NASDAQ: BEAT) Validates ECG Technology with Strong Results in Pivotal Study

HeartBeam is developing a portable, credit-card-sized device and proprietary software capable of capturing heart signals in three non-coplanar dimensions and reconstructing those signals into a full synthesized 12-lead ECG. The importance of such innovation is underscored by the widespread impact of heart disease, such as heart rhythm problems. The VALID-ECG study results carry significant weight for both clinical adoption and HeartBeam’s commercialization pathway. Early and accurate detection of heart rhythm problems can mean the difference between life-saving intervention and a missed opportunity, which is why new advances in cardiac diagnostics carry such weight. HeartBeam (NASDAQ: BEAT) has reported promising results…

TuesdayOct 07, 2025 10:00 am

Lund University Researchers Discover Why Leukemia Cells Evade the Immune System

While immunotherapy has scored a significant level of success in treating many types of cancer, it hasn’t registered similar efficacy in leukemia, especially acute myeloid leukemia, also known as AML. Researchers at Lund University, Sweden have found a possible reason why this could be so. The team sought to identify any unique surface proteins on leukemia cells that could be targeted with new forms of treatment, especially if those unique proteins didn’t exist on healthy cells. Thoas Fioretos, who led the research team, explains that they found one protein on the surface of leukemia stem cells and this particular protein…

TuesdayOct 07, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision enables re-filing of an Abbreviated New Drug Application (“ANDA”) for the company’s KETAFREE(TM) product, which the company has now done. Current ketamine formulations use multidose vials with a toxic preservative, Benzethonium Chloride. U.S. ketamine market is estimated at $750 million annually, presenting a significant commercial opportunity. NRx is also advancing NRX-100 and NRX-101 for suicidal depression and PTSD, both with FDA designations. The move aligns with U.S. policy goals on reshoring drug production and reducing toxic additives. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company,…

FridayOct 03, 2025 10:00 am

Why Health Insurance Credits Led to the Federal Government Shutdown

Lawmakers in the U.S. Congress hit a stalemate in talks to keep the government open and on Wednesday, a shutdown commenced. At the core of the disagreement between GOP lawmakers and their Democratic Party counterparts are the health care tax credits in the Affordable Care Act due to expire at the end of this year and which the Big Beautiful Bill’s provisions don’t include an extension to these tax credits. A lot has been said about the cuts to Medicare and Medicaid under that law, and the refusal to renew those ACA tax credits only piles to the hardship that…

ThursdayOct 02, 2025 10:00 am

Rapid Spread of ‘Nightmare Bacteria’ Triggers Alarm

In 2013, former CDC director Tom Frieden observed that there were rising cases of ‘nightmare bacteria’, a category of bacteria characterized by three deadly attributes; resistance to all or almost all antibiotics, high mortality levels, and their ability to spread antibiotic resistance to other types of bacteria. From this triple threat of these microbes, one can understand why they are described as ‘nightmare bacteria.’ Data shows that cases of these bacteria are increasing at an alarming rate in the U.S. Available statistics indicate that there has been a nearly 70% spike in incidences of nightmare bacteria in the years 2019-2023.…

WednesdayOct 01, 2025 10:30 am

Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment

Sapu Nano received approval from Australia’s Human Research Ethics Committee (“HREC”) to start enrolling patients in clinical trials for Sapu003 Sapu003 uses Sapu Nano’s Deciparticle(TM) technology to deliver more of the Everolimus drug into the bloodstream, which could be more effective than taking the drug in pill form Sapu Nano is a part of a family of companies formed through GMP Biotechnology Limited, which itself is a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited Sapu Nano, part of a group of companies formed through GMP Biotechnology Limited, which is a joint venture between Oncotelic…

WednesdayOct 01, 2025 9:00 am

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-powered PredictBBB.ai Platform Helps Hoth Therapeutics Streamline Candidate Selection in Drug Development

Hoth Therapeutics (NASDAQ: HOTH) is using Lantern Pharma’s (NASDAQ: LTRN) PredictBBB.ai(TM) platform to accelerate development timelines, reduce risk, and improve candidate selection. This technology helps determine whether or not a candidate is able to cross the blood-brain barrier or not, which is a major holdup for many drug development companies. Leadership at both Lantern Pharma and Hoth Therapeutics are enthusiastic about the collaboration and how it can help deliver life-changing therapies for patients. Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed by Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company…